Technical Analysis for KZIA - Kazia Therapeutics Limited - American Depositary Shares

Grade Last Price % Change Price Change
grade B 3.5899 -4.27% -0.16
KZIA closed down 4.27 percent on Friday, March 22, 2019, on 1.56 times normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical KZIA trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 Hammer Candlestick Bullish 0.00%
Mar 22 Lizard Bullish Bullish Day Trade Setup 0.00%
Mar 22 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Doji - Bullish? Reversal 0.00%
Mar 22 Down 3 Days in a Row Weakness 0.00%
Mar 22 Gapped Down Weakness 0.00%
Mar 22 Lower Bollinger Band Touch Weakness 0.00%
Mar 21 Narrow Range Bar Range Contraction -4.27%

Older signals for KZIA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
Biotechnology Cancer ATM Organ Systems Chemotherapy Ovarian Cancer Neuroblastoma Glioma Pharmaceutical Research Diffuse Intrinsic Pontine Glioma
Is KZIA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.68
52 Week Low 2.04
Average Volume 5,850
200-Day Moving Average 3.3534
50-Day Moving Average 3.3389
20-Day Moving Average 3.7055
10-Day Moving Average 3.7733
Average True Range 0.2737
ADX 36.09
+DI 36.4991
-DI 23.361
Chandelier Exit (Long, 3 ATRs ) 3.4489
Chandelier Exit (Short, 3 ATRs ) 3.9211
Upper Bollinger Band 3.978
Lower Bollinger Band 3.433
Percent B (%b) 0.29
BandWidth 14.707867
MACD Line 0.1119
MACD Signal Line 0.1477
MACD Histogram -0.0359
Fundamentals Value
Market Cap 17.34 Million
Num Shares 4.83 Million
EPS -1.80
Price-to-Earnings (P/E) Ratio -1.99
Price-to-Sales 2.05
Price-to-Book 0.71
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.93
Resistance 3 (R3) 3.91 3.77 3.88
Resistance 2 (R2) 3.77 3.68 3.78 3.86
Resistance 1 (R1) 3.68 3.63 3.61 3.70 3.84
Pivot Point 3.54 3.54 3.51 3.55 3.54
Support 1 (S1) 3.45 3.45 3.38 3.48 3.34
Support 2 (S2) 3.31 3.40 3.32 3.32
Support 3 (S3) 3.22 3.31 3.30
Support 4 (S4) 3.25